Novel acylated insulin analog
Novel acylated insulin analogs, formed by a specific acylation reaction, address the need for less frequent insulin injections by offering a once-weekly administration with improved glucose control and compliance.
Patent Information
- Application Number
- JP2023572618
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-05-24
- Filing Date
- 2022-05-23
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2042-05-23
AI Technical Summary
Current insulin therapies require frequent injections, causing discomfort and low patient compliance, and existing insulin analogs do not provide an ideal duration of action for less frequent administration.
Development of novel acylated insulin analogs through an acylation reaction between a side-chain compound and a human insulin analog, incorporating specific fatty acid and diamino compounds, forming amide bonds, to create a longer-acting insulin preparation.
The acylated insulin analogs offer a once-weekly administration option, improving patient compliance and providing effective glucose control with a longer duration of action compared to current preparations.
Smart Images

Figure 0007948968000067 
Figure 0007948968000068 
Figure 0007948968000069
Abstract
Citation Information
Patent Citations
Novel derivative of an insulin analogue
CN105636979A
Insulin analog having acyl and alkylene glycol moieties
JP2010535851A
Protease-stabilized acylated insulin analog
JP2011515358A
Methods for acylation of peptides or proteins
JP2012502083A
Human insulin analogs and their acylated derivatives
JP2015501819A
